WO2008139938A1 - Ciblage d'une molécule d'acide nucléique double brin pour un gène de type 16 du virus du papillome humain, et agent pharmaceutique comprenant la molécule - Google Patents

Ciblage d'une molécule d'acide nucléique double brin pour un gène de type 16 du virus du papillome humain, et agent pharmaceutique comprenant la molécule Download PDF

Info

Publication number
WO2008139938A1
WO2008139938A1 PCT/JP2008/058289 JP2008058289W WO2008139938A1 WO 2008139938 A1 WO2008139938 A1 WO 2008139938A1 JP 2008058289 W JP2008058289 W JP 2008058289W WO 2008139938 A1 WO2008139938 A1 WO 2008139938A1
Authority
WO
WIPO (PCT)
Prior art keywords
double
nucleic acid
stranded nucleic
acid molecule
pharmaceutical agent
Prior art date
Application number
PCT/JP2008/058289
Other languages
English (en)
Japanese (ja)
Inventor
Kenji Yamato
Yukikazu Natori
Masato Fujino
Taketo Yamada
Mitsuo Yoshinouchi
Original Assignee
National University Corporation Tokyo Medical And Dental University
Rnai Co., Ltd.
National University Corporation Okayama University
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation Tokyo Medical And Dental University, Rnai Co., Ltd., National University Corporation Okayama University, Keio University filed Critical National University Corporation Tokyo Medical And Dental University
Priority to JP2009514103A priority Critical patent/JPWO2008139938A1/ja
Publication of WO2008139938A1 publication Critical patent/WO2008139938A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne: une molécule d'acide nucléique double brin (par exemple, ARNsi) qui a une activité inhibitrice élevée sur et une spécificité élevée à l'expression d'un oncogène du type 16 du virus du papillome humain (VPH); et un agent pharmaceutique ou similaire qui est approprié pour le traitement ou la prévention d'une maladie (par exemple, cancer du col de l'utérus) induit par l'infection par le type 16 du VPH. L'invention concerne spécifiquement: une molécule d'acide nucléique double brin qui cible une séquence spécifique située dans chacun des oncogènes du type 16 E6 et E7 du VPH et qui a une activité inhibitrice élevée sur et une spécificité élevée à l'expression du gène; et un ADN, un vecteur et un agent pharmaceutique comprenant la molécule d'acide nucléique double brin.
PCT/JP2008/058289 2007-05-02 2008-04-30 Ciblage d'une molécule d'acide nucléique double brin pour un gène de type 16 du virus du papillome humain, et agent pharmaceutique comprenant la molécule WO2008139938A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009514103A JPWO2008139938A1 (ja) 2007-05-02 2008-04-30 ヒトパピローマウイルス１６型遺伝子を標的とする二本鎖核酸分子及びそれを含む医薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007121498 2007-05-02
JP2007-121498 2007-05-02

Publications (1)

Publication Number Publication Date
WO2008139938A1 true WO2008139938A1 (fr) 2008-11-20

Family

ID=40002151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058289 WO2008139938A1 (fr) 2007-05-02 2008-04-30 Ciblage d'une molécule d'acide nucléique double brin pour un gène de type 16 du virus du papillome humain, et agent pharmaceutique comprenant la molécule

Country Status (2)

Country Link
JP (1) JPWO2008139938A1 (fr)
WO (1) WO2008139938A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012094682A3 (fr) * 2011-01-07 2012-12-06 Qiagen Gaithersburg, Inc. Matériaux et procédé pour le génotypage et la quantification d'un papillomavirus humain à haut risque
US8389219B2 (en) 2000-06-15 2013-03-05 Qiagen Gaithersburg, Inc. Detection of nucleic acids by type-specific hybrid capture method
JP2013118839A (ja) * 2011-12-07 2013-06-17 Bio Think Tank Co Ltd 遺伝子発現阻害剤及び阻害方法
US8722328B2 (en) 2010-01-04 2014-05-13 Qiagen Gaithersburg, Inc. Methods, compositions, and kits for recovery of nucleic acids or proteins from fixed tissue samples
US8735564B2 (en) 2008-10-27 2014-05-27 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and system
US8901287B2 (en) 2004-10-20 2014-12-02 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
JP2015529654A (ja) * 2012-08-02 2015-10-08 アビオン インコーポレーテッド Ｈｐｖ感染に係わる癌の治療用組成物
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
US9410146B2 (en) 2009-09-14 2016-08-09 Qiagen Gaithersburg Inc. Compositions and methods for recovery of nucleic acids or proteins from tissue samples fixed in cytology media
US9422593B2 (en) 2010-05-19 2016-08-23 Qiagen Gaithresburg, Inc Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
US9605303B2 (en) 2010-01-29 2017-03-28 Qiagen Gaithersburg, Inc. Method of determining and confirming the presence of an HPV in a sample
US9689047B2 (en) 2010-01-29 2017-06-27 Qiagen Gaithersburg Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
US9777264B2 (en) 2011-11-03 2017-10-03 Qiagen Gaithersburg, Inc. Materials and method for immobilizing, isolating, and concentrating cells using carboxylated surfaces
US9797000B2 (en) 2009-05-01 2017-10-24 Qiagen Gaithersburg Inc. Non-target amplification method for detection of RNA splice-forms in a sample
US9885092B2 (en) 2011-02-24 2018-02-06 Qiagen Gaithersburg Inc. Materials and methods for detection of HPV nucleic acids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3803318B2 (ja) * 2001-11-21 2006-08-02 株式会社ＲＮＡｉ 遺伝子発現阻害方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3803318B2 (ja) * 2001-11-21 2006-08-02 株式会社ＲＮＡｉ 遺伝子発現阻害方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BUTZ K. ET AL.: "siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells", ONCOGENE, vol. 22, 2003, pages 5938 - 5945, XP002282768, DOI: doi:10.1038/sj.onc.1206894 *
HALL A.H.S. AND ALEXANDER K.A.: "RNA Interferance of Human Papillomavirus Type 18 E6 and E7 Induces Senescence in Hella Cells", J. VIROL., vol. 77, no. 10, May 2003 (2003-05-01), pages 6066 - 6069 *
JIANG M. AND MILNER J.: "Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference", ONCOGENE, vol. 21, 2002, pages 6041 - 6048, XP008011619, DOI: doi:10.1038/sj.onc.1205878 *
PUTRAL L.N. ET AL.: "RNA Interference against Human Papillomavirus Oncogenes in Cervical Cancer Cells Results in Increased Sensitivity to Cisplastin", MOL. PHARMACOL., vol. 68, no. 5, 2005, pages 1311 - 1319, XP008118981, DOI: doi:10.1124/MOL.105.014191 *
UI-TEI K. ET AL.: "Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect", NUCLEIC ACIDS RES., vol. 36, no. 7, 11 February 2008 (2008-02-11), pages 2136 - 2151, XP002598044, DOI: doi:10.1093/nar/gkn042 *
YAMAMOTO K. ET AL.: "Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA", CANCER GENE THER., vol. 13, 2006, pages 234 - 241 *
YAMAMOTO K. ET AL.: "New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer", CANCER GENE THER., vol. 15, 2008, pages 140 - 153, XP002544102, DOI: doi:10.1038/sj.cgt.7701118 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389219B2 (en) 2000-06-15 2013-03-05 Qiagen Gaithersburg, Inc. Detection of nucleic acids by type-specific hybrid capture method
US8557973B2 (en) 2000-06-15 2013-10-15 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US8901287B2 (en) 2004-10-20 2014-12-02 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US9115410B2 (en) 2004-10-20 2015-08-25 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US8735564B2 (en) 2008-10-27 2014-05-27 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and system
US8877436B2 (en) 2008-10-27 2014-11-04 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay on an automated platform
US9797000B2 (en) 2009-05-01 2017-10-24 Qiagen Gaithersburg Inc. Non-target amplification method for detection of RNA splice-forms in a sample
US9410146B2 (en) 2009-09-14 2016-08-09 Qiagen Gaithersburg Inc. Compositions and methods for recovery of nucleic acids or proteins from tissue samples fixed in cytology media
US8722328B2 (en) 2010-01-04 2014-05-13 Qiagen Gaithersburg, Inc. Methods, compositions, and kits for recovery of nucleic acids or proteins from fixed tissue samples
US9689047B2 (en) 2010-01-29 2017-06-27 Qiagen Gaithersburg Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
US9605303B2 (en) 2010-01-29 2017-03-28 Qiagen Gaithersburg, Inc. Method of determining and confirming the presence of an HPV in a sample
US9422593B2 (en) 2010-05-19 2016-08-23 Qiagen Gaithresburg, Inc Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
AU2012204158B2 (en) * 2011-01-07 2017-02-02 Qiagen Gaithersburg, Inc. Materials and method for genotyping and quantifying a high-risk human papillomavirus
WO2012094682A3 (fr) * 2011-01-07 2012-12-06 Qiagen Gaithersburg, Inc. Matériaux et procédé pour le génotypage et la quantification d'un papillomavirus humain à haut risque
US9885092B2 (en) 2011-02-24 2018-02-06 Qiagen Gaithersburg Inc. Materials and methods for detection of HPV nucleic acids
US9777264B2 (en) 2011-11-03 2017-10-03 Qiagen Gaithersburg, Inc. Materials and method for immobilizing, isolating, and concentrating cells using carboxylated surfaces
JP2013118839A (ja) * 2011-12-07 2013-06-17 Bio Think Tank Co Ltd 遺伝子発現阻害剤及び阻害方法
JP2016190845A (ja) * 2012-08-02 2016-11-10 アビオン インコーポレーテッド Ｈｐｖ感染に係わる癌の治療用組成物
AU2013297196B2 (en) * 2012-08-02 2017-01-05 EnhancedBio Inc. Composition for treating cancer associated with HPV infection
EP2881123A4 (fr) * 2012-08-02 2016-07-06 Abion Inc Composition pour le traitement du cancer associé à une infection par le hpv
JP2015529654A (ja) * 2012-08-02 2015-10-08 アビオン インコーポレーテッド Ｈｐｖ感染に係わる癌の治療用組成物
US9719093B2 (en) 2012-08-02 2017-08-01 Abion Inc. Composition for treating cancer associated with HPV infection
EP3178498A3 (fr) * 2012-08-02 2017-09-27 Abion Inc. Composition de traitement du cancer associé à une infection par le papillomavirus humain
US10221418B2 (en) 2012-08-02 2019-03-05 EnhancedBio Inc. Composition for treating cancer associated with HPV infection

Also Published As

Publication number Publication date
JPWO2008139938A1 (ja) 2010-08-05

Similar Documents

Publication Publication Date Title
WO2008139938A1 (fr) Ciblage d'une molécule d'acide nucléique double brin pour un gène de type 16 du virus du papillome humain, et agent pharmaceutique comprenant la molécule
WO2008116860A3 (fr) Compositions d'arn double brin et procédés de traitement d'infections par le virus du papillome humain (hpv)
Artusi et al. The Herpes Simplex Virus-1 genome contains multiple clusters of repeated G-quadruplex: Implications for the antiviral activity of a G-quadruplex ligand
WO2010141511A3 (fr) Polynucléotides pour interférence arn multivalente, compositions et procédés pour les utiliser
WO2003070193A3 (fr) Inhibition induite par interference arn de l'expression du gene vih au moyen d'acides nucleiques interferents courts (sina)
WO2006121464A3 (fr) Compositions pour le traitement d'infections virales respiratoires et utilisations associees
WO2008036825A3 (fr) Complexes d'oligonucléotides bicaténaires et procédés de silençage de gènes par interférence arn
WO2009060124A3 (fr) Utilisation d'oligonucléotides avec des bases modifiées dans l'hybridation d'acides nucléiques
WO2009024834A3 (fr) Acides nucléiques impliques dans les infections virales
WO2003070970A3 (fr) Inhibition de l'expression genique de nf-kappa b/rel-a induite par l'interference d'arn effectuee au moyen d'un acide nucleique interferant court
EA201892285A1 (ru) Нуклеотиды, модифицированные циклофосфонатом по положению 5'
WO2008051928A3 (fr) Amplification ciblée d'un génome entier d'acides nucléiques
WO2010068884A3 (fr) Procédés et systèmes pour le séquençage direct de molécules d'adn individuelles
DE602005022759D1 (de) Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
WO2007143752A3 (fr) Cibles pour le pronostic ou la thérapie dans le cancer du sein
WO2008131191A3 (fr) Acides nucléiques hybridables avec des précurseurs des micro-arn de ceux-ci
WO2014066915A3 (fr) Procédés et compositions pour produire une activité ss-arni ayant une puissance accrue
WO2008030996A3 (fr) Arnsi, et procédés de fabrication
WO2010003420A3 (fr) Traitement du psoriasis et de maladies apparentées par modulation de miarn
Zhang et al. Antisense oligonucleotides targeting the RNA binding region of the NP gene inhibit replication of highly pathogenic avian influenza virus H5N1
WO2005103254A8 (fr) Sequences cibles universelles pour le silençage de genes par siarn
CA2876165C (fr) Conjugues particule-acide nucleique et utilisations therapeutiques associees
WO2007111998A3 (fr) Compositions d'arndb et procedes de traitement d'une infection par l'hpv
WO2009029681A3 (fr) Micro-arn utilisés pour inhiber la réplication virale
WO2008108843A3 (fr) Procédés et kits pour amplifier l'adn

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740957

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2009514103

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08740957

Country of ref document: EP

Kind code of ref document: A1